Zydus Lifesciences Ltd. on Monday said its U.S. unit has received tentative approval from the U.S. Food and Drug Administration to market generic Levomilnacipran extended-release capsules used to treat depression.
Zydus' Generic Levomilnacipran Receives Approval in the U.S.
Zydus' Generic Levomilnacipran Receives Approval in the U.S.
Prinston's Generic Levomilnacipran Receives Approval in the U.S.
MSN Lab`s Generic Levomilnacipran Receives Tentative Approval In US
FDA Confirms Paragraph IV Patent Challenge of Fetzima (Levomilnacipran) Capsules
In September 2016. Allergan (AGN)’s Chief Executive Officer Brent Saunders publicly vowed to keep price increases on the company’s drugs under 10 percent in 2017. Four days into the new year, Saunders has kept his word. On Jan. 1, the Irish company announced nine older drugs would see price increases of 9 to 9.5 percent–staying under that 10 percent mark.